Table 6.

Comparison of ON with and without anti-TNFα in IBD patients

	ON with anti-TNFα (n = 16)	ON without anti-TNFα (n = 10)	P value
Male, n (%)	5 (31)	3 (30)	1
Median age at ON diagnosis, y (IQR)	43 (35 to 48)	36 (26 to 40)*	0.08
Crohn disease, n (%)	10 (62)	4 (40)	0.42
Ulcerative colitis, n (%)	4 (25)	5 (50)	0.23
Indefinite colitis, n (%)	2 (13)	1 (10)	1
Active IBD at onset of ON, n (%)	6 (43)**	2 (25)**	0.65
Median disease duration, y (IQR)	6 (4.5 to 14)*	5 (0.8 to 12.5)**	0.35
IBD medication within 6 months before ON, n (%)
Anti-TNFα	16 (100)	0	-
Corticosteroid	6 (37)	2 (20)	0.42
Azathioprine	5 (31)	0	0.12
Methotrexate	2 (12)	0	0.51
Ocular manifestation, n (%)
Unilateral	14 (87)	7 (78)*	0.61
Median Initial visual acuity (IQR)	0.4 (0.3 to 0.5) ***	0.5 (0.25 to 0.75) ***	0.28
Diagnosis of concomitant MS, n (%)	4 (25)	0	0.14
Treatment
Oral corticosteroid, n (%)	4 (25)	5 (50)	0.23
IV corticosteroid, n (%)	9 (56)	2 (20)	0.11
Interferon, n (%)	3 (19)	0	0.26
Visual outcomes
Total recovery, n (%)	9 (56)	5 (55)*	1
Partial recovery, n (%)	6 (37)	2 (20)	0.42
Stable or Worse, n (%)	1 (6)	2 (20)	0.54
Recurrence, n (%)	2 (12)	0	0.51
Evolution to MS during follow up, n (%)	1 (7)**	0****	1

IBD; inflammatory bowel disease; IQR = interquartile range; MS = Multiple sclerosis; N = number; ON = optic neuritis; TNF = tumor necrosis factor; Y = year(s)

* data missing in 1 patient; ** data missing in 2 patients; *** data missing in 3 patients; **** data missing in 4 patients